A Novel Predictive Model Associated with Osteosarcoma Metastasis

References

• Dorfman HD, Czerniak BJ. Bone cancers. Cancer. 1995;75(S1):203–210.8000997
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–1543. doi:10.1002/cncr.2412119197972
   PubMed Web of Science ®Google Scholar
• Unni KK, Inwards CY. Dahlin’s Bone Tumors: General Aspects and Data on 10,165 Cases. Lippincott Williams & Wilkins; 2010.
   Google Scholar
• Larsson SE, Lorentzon RJ. The incidence of malignant primary bone tumours in relation to age, sex and site: a study of osteogenic sarcoma, chondrosarcoma and Ewing’s sarcoma diagnosed in Sweden from 1958 to 1968. J Bone Joint Surg Br. 1974;56(3):534–540. doi:10.1302/0301-620X.56B3.534
   Google Scholar
• Polednak AP. Primary bone cancer incidence in black and white residents of New York State. Cancer. 1985;55(12):2883–2888. doi:10.1002/1097-0142(19850615)55:12<2883::AID-CNCR2820551231>3.0.CO;2-Q3857961
   PubMed Web of Science ®Google Scholar
• Ji J, Hemminki K. Familial risk for histology-specific bone cancers: an updated study in Sweden. Eur J Cancer. 2006;42(14):2343–2349. doi:10.1016/j.ejca.2005.11.04316859907
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Cancer. 2005;41(18):2836–2845.
   Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–1606.3520317
   PubMed Web of Science ®Google Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49(6):1221–1230. doi:10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E6174200
   PubMed Web of Science ®Google Scholar
• Dong J, Liu Y, Liao W, et al. miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma. J Bone Oncol. 2016;5(2):74–79. doi:10.1016/j.jbo.2016.05.00127335775
   PubMed Web of Science ®Google Scholar
• Wang M, Xie R, Si H, et al. Integrated bioinformatics analysis of miRNA expression in osteosarcoma. Artif Cells Nanomed Biotechnol. 2017;45(5):936–943. doi:10.1080/21691401.2016.119645627315542
   PubMed Web of Science ®Google Scholar
• Di Fiore R, Drago‐Ferrante R, Pentimalli F, et al. Let‐7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma‐derived 3AB‐OS cancer stem cells. J Cell Physiol. 2016;231(8):1832–1841. doi:10.1002/jcp.2529126679758
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol. 2007;25(15):2057–2062. doi:10.1200/JCO.2006.07.777617513810
   PubMed Web of Science ®Google Scholar
• Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99. doi:10.1016/j.pharmthera.2012.09.00322983152
   PubMed Web of Science ®Google Scholar
• Shi J, Dong B, Cao J, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget. 2017;8(16):27582. doi:10.18632/oncotarget.1517528187439
   PubMedGoogle Scholar
• Idogawa M, Ohashi T, Sasaki Y, et al. Long non‐coding RNA NEAT1 is a transcriptional target of p53 and modulates p53‐induced transactivation and tumor‐suppressor function. Int J Cancer. 2017;140(12):2785–2791. doi:10.1002/ijc.3068928295289
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang D, Zheng T, et al. lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2. Oncogenesis. 2020;9(5):54. doi:10.1038/s41389-020-0242-z32467565
   PubMed Web of Science ®Google Scholar
• Gooding AJ, Zhang B, Jahanbani FK, et al. The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence. Sci Rep. 2017;7(1):12698. doi:10.1038/s41598-017-12716-628983112
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang B, Zhang M, et al. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018;33(4):548.
   Web of Science ®Google Scholar
• Kitamura T, Qian BZ, Soong D, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015;212(7):1043–1059. doi:10.1084/jem.2014183626056232
   PubMed Web of Science ®Google Scholar
• Li C, Wang S, Xing Z, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19(2):106–119. doi:10.1038/ncb346428114269
   PubMed Web of Science ®Google Scholar
• Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041. doi:10.1038/sj.onc.120692812970751
   PubMed Web of Science ®Google Scholar
• Shen L, Chen L, Wang Y, et al. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121(1):101–108. doi:10.1007/s11060-014-1613-025217850
   PubMed Web of Science ®Google Scholar
• Ying L, Chen Q, Wang Y, et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012;8(9):2289–2294. doi:10.1039/c2mb25070e22722759
   PubMedGoogle Scholar
• Fan Y, Shen B, Tan M, et al. TGF-β–induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20(6):1531–1541. doi:10.1158/1078-0432.CCR-13-145524449823
   PubMed Web of Science ®Google Scholar
• Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–1625. doi:10.1038/onc.2012.19322614017
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48(3):R45–R53. doi:10.1530/JME-12-000822393162
   PubMed Web of Science ®Google Scholar
• Peng W, Si S, Zhang Q, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Mol Endocrinol. 2015;34(1):1–10.
   Google Scholar
• Hou CH, Lin FL, Hou SM, et al. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer. 2014;13(1):1–13. doi:10.1186/1476-4598-13-23624387052
   PubMed Web of Science ®Google Scholar
• Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8(10):705–718.21317869
   PubMedGoogle Scholar
• Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292–315. doi:10.1081/CNV-10010255711338887
   PubMed Web of Science ®Google Scholar
• He M, Wang G, Jiang L, et al. miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway. Int J Oncol. 2017;50(5):1590–1600. doi:10.3892/ijo.2017.392828339053
   PubMed Web of Science ®Google Scholar
• Li G, Zhang H, Wan X, et al. Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma. Biomed Res Int. 2014;2014:780521.24757675
   PubMed Web of Science ®Google Scholar
• Maass PG, Luft FC, Bähring S. Long non-coding RNA in health and disease. J Mol Med (Berl). 2014;92(4):337–346. doi:10.1007/s00109-014-1131-824531795
   PubMed Web of Science ®Google Scholar
• Tripathi V, Shen Z, Chakraborty A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9(3):e1003368. doi:10.1371/journal.pgen.100336823555285
   PubMed Web of Science ®Google Scholar
• Zhang A, Xu M, Mo YY. Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol. 2014;Jun(3):181–191. doi:10.1093/jmcb/mju013
   Web of Science ®Google Scholar
• Kumarswamy R, Bauters C, Volkmann I, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114(10):1569–1575. doi:10.1161/CIRCRESAHA.114.30391524663402
   PubMed Web of Science ®Google Scholar
• Lobos-González L, Silva V, Araya M, et al. Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors. Oncotarget. 2016;7(36):58331. doi:10.18632/oncotarget.1111027507060
   PubMedGoogle Scholar
• Varas‐Godoy M, Lladser A, Farfan N, et al. In vivo knockdown of antisense non‐coding mitochondrial RNA s by a lentiviral‐encoded sh RNA inhibits melanoma tumor growth and lung colonization. Pigment Cell Melanoma Res. 2018;31(1):64–72. doi:10.1111/pcmr.1261528707763
   PubMed Web of Science ®Google Scholar
• Borgna V, Villegas J, Burzio VA, et al. Mitochondrial ASncmtRNA-1 and ASncmtRNA-2 as potent targets to inhibit tumor growth and metastasis in the RenCa murine renal adenocarcinoma model. Oncotarget. 2017;8(27):43692. doi:10.18632/oncotarget.1846028620146
   PubMedGoogle Scholar
• Zhong YH, Cheng HZ, Peng H, et al. Heat shock factor 2 is associated with the occurrence of lung cancer by enhancing the expression of heat shock proteins. Oncol Lett. 2016;12(6):5106–5112. doi:10.3892/ol.2016.536828101237
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Wu W, et al. Expression of the Nrf2 and Keap1 proteins and their clinical significance in osteosarcoma. Biochem Biophys Res Commun. 2016;473(1):42–46. doi:10.1016/j.bbrc.2016.03.04726987716
   PubMed Web of Science ®Google Scholar
• Bandala C, Ávila-luna A, Gómez-López M, et al. Catecholamine levels and gene expression of their receptors in tissues of adults with osteosarcoma. Arch Physiol Biochem. 2019;10:1–7.
   Google Scholar
• Tanaka M, Setoguchi T, Hirotsu M, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer. 2009;100(12):1957–1965. doi:10.1038/sj.bjc.660506019455146
   PubMed Web of Science ®Google Scholar
• Dai G, Liu G, Zheng D, et al. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma. Eur J Pharmacol. 2021;15(899):174058. doi:10.1016/j.ejphar.2021.174058
   Web of Science ®Google Scholar
• Fang L, Li B, Yu D, et al. Analysis of changes in the expression of Notch1 and HES1 and the prognosis of osteosarcoma patients following surgery. Oncol Lett. 2020;20(4):1. doi:10.3892/ol.2020.1215632774475
   PubMed Web of Science ®Google Scholar
• Cheng D, Li J, Li S, et al. CNOT 1 cooperates with LMNA to aggravate osteosarcoma tumorigenesis through the Hedgehog signaling pathway. Mol Oncol. 2017;11(4):388–404. doi:10.1002/1878-0261.1204328188704
   PubMed Web of Science ®Google Scholar
• Guo M, Cai C, Zhao G, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1α activation in human osteosarcoma. PLoS One. 2014;9(3):e90518. doi:10.1371/journal.pone.009051824618817
   PubMed Web of Science ®Google Scholar
• Ji T, Guo Y, Kim K, et al. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma. Mol Cancer. 2015;14(1):1–14. doi:10.1186/s12943-015-0359-425560632
   PubMed Web of Science ®Google Scholar
• Jones KB. Dendritic Cells Drive Osteosarcomagenesis through Newly Identified Oncogene and Tumor Suppressor. Cancer Discov. 2019;9(11):1484–1486. doi:10.1158/2159-8290.CD-19-099431676561
   PubMed Web of Science ®Google Scholar
• Yang M, Ma C, Liu S, et al. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology. 2009;128(1pt2):e237–e249. doi:10.1111/j.1365-2567.2008.02954.x19740309
   PubMed Web of Science ®Google Scholar